MOLLI® 2 System offers breast cancer patients
enhanced comfort and unmatched surgical precision
CHARLESTON, S.C. and DEERFIELD, Ill., July 25,
2024 /PRNewswire/ -- MUSC Hollings Cancer
Center, an NCI-designated cancer center within the Medical University of South Carolina (MUSC), the
state's only comprehensive academic health system, is
partnering with MOLLI Surgical to adopt the MOLLI® 2 System. The
award-winning wire-free and radiation-free technology for
localizing lesions for breast cancer surgery improves the patient
experience and has earned praise from surgeons for its accuracy and
ease of use.
"Hollings has adopted the MOLLI 2 System in order to treat
our patients with the most accurate, advanced technology
available," said Andrea Abbott,
M.D., a surgical oncologist and medical director of the
Comprehensive Breast Program at Hollings. "MOLLI 2 provides precise
feedback while localizing the lesion; the information is
instantaneous and allows for efficiency and accuracy. And patients
appreciate the flexibility of having the MOLLI® Marker placed ahead
of time instead of adding another procedure to the day of
surgery."
The MOLLI 2 System is an innovative technology that allows
radiologists to mark lesions with the MOLLI Marker, a localization
device roughly the size of a sesame seed. The device can be placed
up to 30 days before surgery, allowing radiology to make the best
use of time in the mammography suite without the need to
synchronize schedules with surgery. Surgeons then use the MOLLI®
Wand and MOLLI® Tablet to locate the lesion marked in radiology
reliably, eliminating the need for wire-guided localization. The
technology features a market-leading innovation — directional 3D
guidance — which enables MOLLI 2 to direct surgeons to the lesion
with millimeter precision. The MOLLI 2 System is easy to use,
reliable, and precise, improving efficiency and enhancing the
patient experience.
"MUSC makes a profound impact on its community as the state's
only comprehensive academic health system. Given its wide reach to
patients and medical students, we're honored to be selected as a
partner to provide precision surgery solutions," said Ananth Ravi, President and CEO of MOLLI
Surgical. "MUSC's dedication to advancing patient-centric breast
cancer care is further affirmed by their adoption of MOLLI 2."
Team members at Hollings have found it easy to integrate the
MOLLI 2 System into their existing workflows and operating rooms.
"There was essentially no learning curve to implement MOLLI 2 and
begin using it in the operating room. The device setup was simple
and easy for everyone; the physicians, the OR staff, and the
radiology team were all able to quickly add MOLLI 2 into their
patient care," said Dr. Abbott.
With the introduction of MOLLI 2, MUSC and MOLLI Surgical
demonstrate their dedication to enabling precision surgery made
simpler, elevating clinical efficiency, and enhancing the patient
and physician experience.
About MUSC Hollings Cancer Center:
MUSC Hollings
Cancer Center is South Carolina's
only National Cancer Institute-designated cancer center with the
largest academic-based cancer research program in the state. The
cancer center comprises more than 140 faculty cancer scientists and
20 academic departments. It has an annual research funding
portfolio of more than $50 million
and sponsors more than 200 clinical trials across the state.
Dedicated to preventing and reducing the cancer burden statewide,
the Hollings Office of Community Outreach and Engagement works with
community organizations to bring cancer education and prevention
information to affected populations. Hollings offers
state-of-the-art cancer screening, diagnostic capabilities,
therapies, and surgical techniques within its multidisciplinary
clinics. Hollings specialists include surgeons, medical
oncologists, radiation oncologists, radiologists, pathologists,
psychologists, and other clinical providers equipped to provide the
full range of cancer care. For more information, visit
hollingscancercenter.musc.edu.
About MOLLI Surgical:
MOLLI Surgical started with one
patient, who asked if there was a way to make her breast cancer
journey better. Her voice led to the creation of our flagship wire
and radiation-free technologies — MOLLI® 2 and MOLLI re.markable™.
Our innovations are intended to replace outdated procedures to mark
lesions for surgical removal through greater precision, efficiency,
and cost-effectiveness. We are obsessed with every detail of our
design process to ensure surgeons and radiologists have the best
possible tools to support an improved patient experience.
MOLLI® has been recognized by TIME as one of 2022's "Best
Inventions" in the Medical Care category and named to Fast
Company's list of "Next Big Things in Tech," recognizing
technological breakthroughs across industries that promise to
transform the future. We are proud to build the advanced solutions
that patients and physicians prefer. Follow us on Facebook,
LinkedIn, X, and YouTube.
Press Contact:
Grace
Halvorsen
gracehalvorsen@lightspeedpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/the-medical-university-of-south-carolina-becomes-first-in-south-carolina-to-adopt-molli-surgicals-advanced-breast-cancer-technology-302205983.html
SOURCE MOLLI Surgical